CDKN2B antibody
Quick Overview for CDKN2B antibody (ABIN706166)
Target
See all CDKN2B AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Purpose
- CDKN2B/p15 INK4b Polyclonal Antibody
-
Cross-Reactivity
- Chicken, Cow, Dog, Human, Mouse, Rat
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human CDKN2B
-
Isotype
- IgG
-
-
-
-
Application Notes
- WB(1:300-5000), IHC-P(1:200-400), IF(IHC-P)(1:50-200)
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C for 12 months.
-
Expiry Date
- 12 months
-
-
- CDKN2B (Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) (CDKN2B))
-
Alternative Name
- CDKN2B
-
Background
-
Synonyms: CDK inhibitory protein, CDK4B Inhibitor, CDKN2B, Cyclin dependent kinase 4 inhibitor B, Cyclin Dependent Kinase Inhibitor 2B, Cyclin dependent kinase inhibitor 2B p15 inhibits CDK4, Cyclin-dependent kinases 4 and 6 binding protein, INK4B, MTS 2, MTS2, Multiple Tumor Supressor 2, p14 CDK inhibitor, p14 INK4b, P15, p15 CDK inhibitor, p15 inhibits CDK4, p15 INK4b, P15INK4B, p15INK4B, TP 15, TP15.
Background: p15 INK4b / MTS 2 (Mitotic Inhibitor / Suppressor Protein) is a specific inhibitor of cdk 4 / cdk 6 and is periodically expressed during the cell cycle. Reportedly, p15 INK4b expression is induced approximately 30 fold in human keratinocytes by treatment with TGF beta, suggesting that p15 INK4b may act as an effector of TGF beta mediated cell cycle arrest. p15 INK4b is mapped to chromosome 9p21, a region of frequent loss in a wide variety of cancers.
-
Molecular Weight
- 15kDa
-
Gene ID
- 1030
-
UniProt
- P42772
-
Pathways
- Cell Division Cycle, Mitotic G1-G1/S Phases
Target
-